EC Number   |
Application |
Reference |
|---|
    1.1.1.49 | drug development |
the enzyme is a target for anti-parasite drug development |
730067 |
| 1.1.1.49 | drug development |
Trypanosoma brucei G6PDH is a valid drug target for human steroids. Inhibition of G6PDH by dehydroepiandrosterone derivatives may lead to the development of a new class of anti-trypanosomatid compounds |
-, 696748 |
| 1.1.1.49 | industry |
production of abundant intermediates for industrially erythritol production |
-, 704746 |
| 1.1.1.49 | medicine |
fluoride-containing bioactive glasses as used in tissue engineering as well as bone repair, inhibit the pentose phosphate oxidative pathway and the glucose 6-phosphate dehydrogenase activity. The effects are ascribable to the fluoride content/release of glass powders, they are mimicked by NaF solutions and are prevented by radical scavengers dimethyl sulfoxide and tempol, by superoxide dismutase, and by glutathione, but not by apocynin |
711728 |
| 1.1.1.49 | medicine |
G6PD deficiency due to its polymorphism causes neonatal jaundice, acute hemolysis in malaria, favism, severe chronic non-spherocytic hemolytic anemia, and lipid dysregulation. G6PD deficiency may be responsible for the high incidence of coronary artery disease among African-Americans and reduces mortality due to ischemic heart disease and cerebrovascular disease in Sardinian males. In Mediterranean and Sardinian G6PD-deficient individuals, G6PD deficiency may confer a partial protection against atherosclerosis, leading to a reduced risk of cardiovascular diseases in G6PD-deficient individuals. G6PD appears to be an attractive therapeutic target for diabetes-induced cardiomyopathy, ischemic cardiomyopathy, pulmonary hypertension, angiotensin II-induced hypertension, vascular smooth muscle hypertrophy and coronary disease in humans |
697523 |
| 1.1.1.49 | medicine |
G6PD deficiency is the commonest clinically significant enzymopathy in humans. More than 400 million people worldwide are affected by this condition which may determine favism, drug-induced acute hemolytic anemia, severe chronic nonspherocytic haemolytic anemia, neonatal jaundice and hemolytic anemia associated with viral or microbiological infections. The highest prevalence of G6PD deficiency mainly regards tropical Africa, the Middle East, tropical and subtropical Asia, Papua New Guinea, and various Mediterranean regions, for example Sardinia island. G6PD deficiency may represent a selective advantage due to the increased resistance to severe Plasmodium falciparum infection of the affected individuals. G6PD/pyruvate kinase ratio is more reliable than the G6PD activity alone, for the identification of G6PD heterozygotes, especially in patients with microcytic anemia. G6PD/6PDG ratio is an absolute measure of G6PD deficiency of female carriers |
698392 |
| 1.1.1.49 | medicine |
in Vietnam the blackwater fever syndrome is associated with malaria infection, quinine ingestion and G6PD deficiency. G6PD deficiency is a major risk factor for haemoglobinuria in ethnic Vietnamese Kinh and within the G6PD deficient population G6PD Viangchan is significantly associated with haemoglobinuria |
699960 |
| 1.1.1.49 | medicine |
refolding protocol can be applied to produce high recovery yield of folded protein with unaltered properties, paving the way for future studies on clinical G6PD mutants with folding defects and providing a useful model system to study the folding process of oligomeric proteins |
696962 |
| 1.1.1.49 | more |
because isoenzyme replacement of G6PDH in the cytosol of tobacco is beneficial under various kinds of cues, this strategy may be a tool to enhance stress tolerance in general |
701015 |
| 1.1.1.49 | more |
evaluation and optimization of enzyme production in Candida guilliermondii, modeling, overview |
-, 676917 |
